The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories ยท page 18 of 23

Stories

  1. Lee's Pharmaceutical posts Phase 3 results for ciprofloxacin-fluocinolone ear drops

    Lee's Pharmaceutical Limited posted results on October 13, 2026 for a Phase 3 trial of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution. The record lists clinical cure for 249 of 295 participants on the combination and 213 of 297 on ciprofloxacin alone.

  2. Huons Biopharma registers Phase 3 trial of HU-045 in glabellar lines

    The study was first posted on ClinicalTrials.gov on October 13, 2026. It plans to enroll 390 participants and compares HU-045 to Xeomin in adults with moderate or severe glabellar lines.

  3. New Phase 3 trials registered, week of October 12, 2026: 10 industry trials

    Industry sponsors registered 10 Phase 3 trials on ClinicalTrials.gov in the week of October 12 to 18, 2026. They plan to enroll 22,480 participants in all; the largest, GlaxoSmithKline's RZV vaccine trial, plans to enroll 16,390.

  4. Phase 3 results posted, week of October 12, 2026: 11 industry trials

    Industry sponsors posted results for 11 Phase 3 trials on ClinicalTrials.gov in the week of October 12 to 18, 2026. Together the trials enrolled 4,030 participants; the largest, Sanofi's AERIFY-1 trial, enrolled 1,127.

  5. Il-Yang Pharm. Co. registers Phase 3 trial of UROCOM-R1 plus UROCOM-R2

    The study plans to enroll 660 participants and is expected to start on November 9, 2026. It plans to compare the efficacy and safety of UROCOM-R1 plus UROCOM-R2 combination therapy with UROCOM-R1 or UROCOM-R2 monotherapy in patients with benign prostatic hyperplasia.

  6. Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis

    Takeda plans to enroll 644 participants in a Phase 3b study of Zasocitinib (TAK-279) for active psoriatic arthritis, with a start date of January 11, 2027. The trial is expected to reach primary completion on April 18, 2030.

  7. GlaxoSmithKline registers Phase 3a study of recombinant zoster vaccine for cardiovascular events

    The study, led by GlaxoSmithKline, plans to enroll 16,390 participants and aims to evaluate the impact of RZV on major adverse cardiovascular events in adults 50 years and older with established cardiovascular disease or two or more risk factors. It is scheduled to begin on November 30, 2026, with primary completion expected on November 25, 2032.

  8. Lee's Pharmaceutical posts results of Phase 3 ciprofloxacin-fluocinolone otic solution trial

    The study enrolled 600 participants and was completed in October 2021. It evaluated the efficacy and safety of ciprofloxacin 0.3% plus fluocinolone acetonide 0.025% otic solution versus ciprofloxacin 0.3% alone in acute otitis externa.

  9. Good Molecules posts results of Phase 3 facial toner study

    The study enrolled 49 participants and evaluated a topical facial toner for improving skin lightness, texture and appearance in hyperpigmentation over 18 weeks. Results were first posted on ClinicalTrials.gov on October 13, 2026.

  10. Sanofi posts AERIFY-2 itepekimab COPD results: exacerbation rates in former smokers

    Sanofi and Regeneron Pharmaceuticals posted results for the Phase 3 AERIFY-2 trial of itepekimab in moderate-to-severe COPD on October 9, 2026. In former smokers, the annualized exacerbation rate was 0.879 on placebo and 0.770 on itepekimab every 4 weeks.

  11. Roche posts IMpower030 results: atezolizumab before surgery in resectable lung cancer

    Hoffmann-La Roche posted results for the Phase 3 IMpower030 trial on October 9, 2026. In the Stage IIB-IIIB wild-type group, median event-free survival was 34.92 months on placebo and 62.78 months on atezolizumab, both plus chemotherapy.

  12. Atezolizumab, ibogaine, and GlaxoSmithKline: the issue of October 5, 2026

    The week of October 5 to 11, 2026: 44 briefs, 9 stories, led by atezolizumab, ibogaine, and GlaxoSmithKline.